Hemostemix CEO Thomas Smeenk joined Steve Darling from Proactive to share news about the company that is using stem cell therapy to aid in a number of diseases. Smeenk telling Proactive more about their lead product ACP-01 which is looking to treat CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients and right now is the subject of a randomized, placebo-controlled, double blind trial for safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. Smeenk also talked about what to expect this year including Phase 2 trial results.
Hemostemix using cell therapy to aid in the fight against cardiovascular disease
